| Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial 2024 · nicotinamide · Adults with stage IV lung adenocarcinoma and EGFR mutations | 1 g | — | 55 |
| Efficacy of intermittent topical 5-fluorouracil 5% and oral nicotinamide in the skin field cancerization: a randomized clinical trial 2021 · Nicotinamide · Adults with actinic keratoses (AKs), mean age 71.6 years; 36 patients were randomized across study groups | 1 g | 120 days | 18 |
| A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention 2015 · nicotinamide group · Adults with at least two nonmelanoma skin cancers in the previous 5 years | 1 g | 1 year | — |
| Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2 2007 · Niacin · Men and women older than 30 years with known coronary vascular disease, receiving statin therapy and with LDL cholesterol below 130 mg/dL and HDL cholesterol below 45 mg/dL | 500 mg | 1 year | 87 |
| Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions 1997 · aspirin 325 mg pretreatment · Healthy adults aged 35–65 years, male and female | 500 mg | 4 days | 42 |
| Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions 1997 · aspirin 650 mg pretreatment · Healthy adults aged 35–65 years, male and female | 500 mg | 4 days | 42 |
| The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] 2003 · niacin group · Healthy volunteers aged 20–60 years | 500 mg | 1 day | 33 |
| Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study 2017 · Group 1 (cases) · Organ transplant recipients with single or multiple actinic keratoses; age and sex not reported | 500 mg | 26 weeks | 19 |
| Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia 2009 · NER starting dose 500 mg/day · Patients with dyslipidemia; age and sex not specified | 500 mg | 4 weeks | — |
| HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment 2013 · ERN/LRPT · Adults with pre-existing occlusive arterial disease at high risk of vascular events, receiving statin-based LDL-lowering therapy; mean age 64.9 years, 82.7% male | 2 g | 1424 days | 12,838 |
| Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial 2019 · niacin-laropiprant · Patients at high risk of vascular disease | 2 g | 1424 days | 12,838 |
| Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial 2012 · E/S+N · Men and women aged 18–79 with type IIa/IIb hyperlipidemia; some had diabetes at baseline and some did not. | 2 g | 64 weeks | 670 |
| Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B 1990 · niacin and colestipol · Men aged 62 or younger with apolipoprotein B levels of at least 125 mg/dL, documented coronary artery disease, and a family history of vascular disease | 4 g | 913 days | 48 |
| Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS) 2013 · Simvastatin & Niacin · Men younger than 63 and women younger than 70 with clinical coronary disease, low HDL cholesterol, and restricted LDL cholesterol and triglycerides | 2 g | 3 years | 33 |
| Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group 1994 · NCT · Patients with recent-onset insulin-dependent diabetes, diagnosed less than 4 weeks earlier; age and sex not reported | 25 mg/kg | 1 year | 30 |
| Nicotinamide and tetracycline therapy of bullous pemphigoid 1994 · nicotinamide and tetracycline group · Patients with bullous pemphigoid; age and sex not reported | 1.5 g | 1 year | 12 |
| Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial 2016 · extended-release niacin (ERN) · Adults with established stable atherosclerotic cardiovascular disease, low HDL-C, elevated triglycerides, and LDL-C below 180 mg/dL | 2 g | 3 years | — |
| Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) 1995 · niacin plus colestipol · Men aged 62 years or younger with coronary artery disease and apolipoprotein B levels of at least 125 mg/dL | 4 g | 913 days | — |
| Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B 1993 · colestipol plus niacin intensive therapy · Asymptomatic men with apolipoprotein B ≥125 mg/dL, a positive family history, and coronary atherosclerosis | 4 g | 913 days | — |
| Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia 2008 · ERN · Adults with dyslipidaemia (primary hypercholesterolaemia or mixed dyslipidaemia) | 1 g | 24 weeks | 543 |
| Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19 2025 · COVit-2 nicotinamide · Adults aged 18–75 with recent mild-to-moderate COVID-19 and at least one symptom; the RFITT primary-analysis population also had at least one risk factor for severe COVID-19 | 1 g | 4 weeks | 448 |
| Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial 2008 · ER niacin 1 g → placebo (N1/P/P) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate | 1 g | 7 days | 51 |
| Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial 2008 · ER niacin 1 g (N1/N1/N1) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate | 1 g | 8 weeks | 45 |
| Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans 2012 · Oral nicotinamide · Healthy volunteers; age and sex not reported | 1 g | 7 days | 30 |
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia 2008 · ERN 1 g · Dyslipidemic patients | 1 g | 8 weeks | — |
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia 2008 · ERN 1 g plus LRPT 18.75 mg, then doubled doses · Dyslipidemic patients | 1 g | 8 weeks | — |
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia 2008 · ERN 1 g plus LRPT 37.5 mg, then doubled doses · Dyslipidemic patients | 1 g | 8 weeks | — |
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia 2008 · ERN 1 g plus LRPT 75 mg, then doubled doses · Dyslipidemic patients | 1 g | 8 weeks | — |
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia 2008 · ERN 1 g plus LRPT 150 mg, then doubled doses · Dyslipidemic patients | 1 g | 8 weeks | — |
| Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study 2009 · niacin (N) · Patients with coronary artery disease; age and sex not specified | 1 g | 12 weeks | — |
| Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia 2009 · NER starting dose 1000 mg/day · Patients with dyslipidemia; age and sex not specified | 1 g | 4 weeks | — |
| Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study 2013 · nicotinamide group · Adults with chronic kidney disease and refractory uremic pruritus; age and sex not reported | 1 g | 4 weeks | — |
| Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial 2014 · ERN monotherapy · Men and women aged 20–60 years with plasma HDL-C below 40 mg/dL | 1 g | 7 days | — |
| Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial 2014 · ERN/laropiprant · Men and women aged 20–60 years with plasma HDL-C below 40 mg/dL | 1 g | 7 days | — |
| Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group 1994 · NCT + CyA · Patients with recent-onset insulin-dependent diabetes, diagnosed less than 4 weeks earlier; age and sex not reported | 25 mg/kg | 1 year | 30 |
| Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy 2013 · ER niacin · Adults with established coronary artery disease receiving high-dose statin therapy; mean age 57.9 years | 1.5 g | 90 days | 66 |
| Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial 2020 · nicotinamide, first dose period · adults with diagnosed and treated glaucoma; age and sex not specified | 1.5 g | 6 weeks | 57 |
| Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial 2020 · nicotinamide, second dose period · adults with diagnosed and treated glaucoma; age and sex not specified | 3 g | 6 weeks | 57 |
| Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study 1994 · Group A · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus | 25 mg/kg | 1 year | 18 |
| Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study 1994 · Group B · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus | 25 mg/kg | 1 year | 18 |
| High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution 2002 · niacin-treated patients · HIV-infected patients with intra-abdominal fat area greater than 70 cm² | 3 g | 1 year | 16 |
| Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment 2006 · niacin group · men with isolated low HDL cholesterol and reduced flow-mediated dilation; age not reported | 1.5 g | 90 days | 11 |
| Effect of altering substrate availability on metabolism and performance during intense exercise 2000 · NA (carbohydrate + nicotinic acid) · Seven highly trained men | 20 mg/kg | 1 day | 7 |
| Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation 2006 · reformulated niacin ER · healthy male volunteers | 2 g | 1 day | — |
| Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation 2006 · commercial niacin ER · healthy male volunteers | 2 g | 1 day | — |
| Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation 2007 · Placebo with niacin ER · Healthy men | 2 g | 1 day | — |
| Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients 2010 · niacin · Adults with statin-treated type 2 diabetes and endothelial dysfunction; LDL-cholesterol ≤2.5 mmol/L | 1.5 g | 20 weeks | — |
| Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia 2011 · niacin group · Men with erectile dysfunction and dyslipidemia | 1.5 g | 12 weeks | — |
| Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy 2010 · NER/S (niacin extended-release/simvastatin) · Men and women aged 21 years or older with primary type II hyperlipidemia or mixed dyslipidemia | 1 g | 12 weeks | 82 |
| Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]) 2003 · niacin ER/lovastatin · Adults with elevated LDL cholesterol and low HDL cholesterol, with or without coronary artery disease | 1 g | 16 weeks | — |
| Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia 1991 · 1000 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles | 1 g | — | — |
| Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus 2012 · ERN/LRPT · Patients with type 2 diabetes mellitus; age and sex not specified | 1 g | 12 weeks | — |
| Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia 1994 · nicotinic acid · Patients with type IIa or IIb primary hypercholesterolemia; age and sex not reported | 1 g | 88 weeks | — |
| Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia 1994 · combination therapy · Patients with type IIa or IIb primary hypercholesterolemia; age and sex not reported | 1 g | 88 weeks | — |
| Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS) 2013 · Simvastatin, Niacin & Antioxidant vitamins · Men younger than 63 and women younger than 70 with clinical coronary disease, low HDL cholesterol, and restricted LDL cholesterol and triglycerides | 2 g | 3 years | 39 |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 16 mg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 20 mg | — | — |
| Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial 2008 · ER niacin 1 g → ER niacin 2 g (N1/N1/N2) · Men and women aged 18–70 for whom extended-release niacin treatment was appropriate | 3 g | 8 weeks | 46 |
| Apple pectin for the reduction of niacin-induced flushing 2013 · apple pectin · Niacin-naïve subjects; age and sex not specified | 1 g | 1 day | 25 |
| Apple pectin for the reduction of niacin-induced flushing 2013 · apple pectin + aspirin · Niacin-naïve subjects; age and sex not specified | 1 g | 1 day | 25 |
| Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation 2007 · Aspirin 30 minutes before niacin ER · Healthy men | 2 g | 1 day | — |
| Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation 2007 · Aspirin concomitantly with niacin ER · Healthy men | 2 g | 1 day | — |
| A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group 1998 · immediate-release niacin · Patients with combined hyperlipidemia or isolated hypertriglyceridemia | 3 g | 12 weeks | 53 |
| Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease 1997 · Regular niacin regimen · 29 male patients with hyperlipidemia and coronary artery disease | 2 g | 240 days | 29 |
| Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial 2011 · treatment group · Korean adults with mixed dyslipidemia | 1.5 g | 8 weeks | 25 |
| Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins 2008 · extended-release niacin (Niaspan) · men aged 44–69 with combined hyperlipidemia | 2 g | 12 weeks | 5 |
| Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins 2008 · extended-release niacin plus lovastatin (Advicor) · men aged 44–69 with combined hyperlipidemia | 2 g | 12 weeks | 5 |
| Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia 2008 · E/S + N · Patients with type IIa or IIb hyperlipidemia | 2 g | 24 weeks | — |
| Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia 2008 · N · Patients with type IIa or IIb hyperlipidemia | 2 g | 24 weeks | — |
| Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy 2009 · simvastatin 20 mg/Niacin-ER 2G (S20/N) · Adults aged 18–90 with carotid atherosclerosis | 2 g | 1 year | — |
| Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia 1991 · 2000 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles | 2 g | — | — |
| Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia 1991 · 1500 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles | 1.5 g | — | — |
| Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia 1991 · 1250 mg niacin group · Male and female subjects aged 20 to 70 years with elevated LDL cholesterol values in the 75th to 95th percentiles | 1.25 g | — | — |
| Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome 2010 · E/S (10/20 mg) + extended-release niacin for 64 weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither | 2 g | 64 weeks | — |
| Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome 2010 · Niacin for 24 weeks, followed by E/S (10/20 mg) + niacin (2 g) for 40 additional weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither | 2 g | 24 weeks | — |
| Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome 2010 · Niacin for 24 weeks, followed by E/S (10/20 mg) + niacin (2 g) for 40 additional weeks · Hyperlipidaemic patients with diabetes mellitus, metabolic syndrome without diabetes, or neither | 2 g | 40 weeks | — |
| Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy 2017 · statin + ER niacin · Adults with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia | 1.5 g | 1 year | — |
| Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy 1994 · fluvastatin+niacin combination · men and women with hypercholesterolemia; age range not reported | 3 g | 9 weeks | — |
| Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy 1994 · placebo+niacin combination · men and women with hypercholesterolemia; age range not reported | 3 g | 9 weeks | — |
| Fluvastatin with and without niacin for hypercholesterolemia 1994 · Fluvastatin group with niacin added · Patients with hypercholesterolemia and plasma LDL cholesterol levels at least 160 mg/dl after an American Heart Association phase 1 diet; age and sex not reported | 3 g | 9 weeks | — |
| Fluvastatin with and without niacin for hypercholesterolemia 1994 · Placebo group with niacin added · Patients with hypercholesterolemia and plasma LDL cholesterol levels at least 160 mg/dl after an American Heart Association phase 1 diet; age and sex not reported | 3 g | 9 weeks | — |
| Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial 1994 · niacin · Patients with primary hypercholesterolemia; age and sex not reported | 1.5 g | 26 weeks | — |
| Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin 1996 · lovastatin 20 mg/day and niacin 500 mg 3 times/day · Patients with fasting LDL cholesterol concentrations of at least 150 mg/dl after dietary stabilization and washout of cholesterol-lowering drugs | 1.5 g | — | — |
| Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia 1998 · Plain niacin, 3.0 g/day phase · Adult men and women with primary hypercholesterolemia | 3 g | 16 weeks | — |
| Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER) 2022 · Experimental group (SINR) · Men and women aged 45–74 with type 2 diabetes and symptomatic distal sensorimotor diabetic polyneuropathy | 50 mg | 85 days | 108 |
| Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy 2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years | 18 mg | 26 weeks | 36 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS · Apparently healthy, resistance-trained males; mean age about 21 years | 60 mg | 8 weeks | 27 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS + S · Apparently healthy, resistance-trained males; mean age about 22 years | 60 mg | 8 weeks | 26 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 60 mg | 1 day | 25 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS + S · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 60 mg | 1 day | 25 |
| Short-Term Effects of a Ready-to-Drink Pre-Workout Beverage on Exercise Performance and Recovery 2017 · RTD · Recreationally active men and women aged 18–40 years with at least six months of resistance-training experience | 65 mg | 7 days | 25 |
| Improved cycling time-trial performance after ingestion of a caffeine energy drink 2009 · Red Bull Energy Drink · Trained male and female cyclists; mean age 27.3 years | 40 mg | 1 day | 12 |
| Effects of vitamin-B complex supplementation on periodontal wound healing 2005 · Vit-B · Adults with generalized moderate to severe chronic periodontitis undergoing access flap surgery; ages not reported; 13 males and 17 females enrolled across the study | 50 mg | 30 days | — |
| Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease 2015 · statin-NER combination · Patients with ischemic nephropathy and a history of at least 5 years of diabetes mellitus or 10 years of hypertension; age and sex not reported | 500 mg | 16 weeks | 51 |
| Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan 2006 · niacin extended-release/lovastatin tablets · Taiwanese patients with dyslipidemia | 500 mg | 16 weeks | 36 |
| Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients 2012 · nicotinic acid group · Hemodialysis patients with serum phosphorus above 6 mg/dL | 500 mg | 4 weeks | 20 |
| The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients 2009 · niacinamide · Peritoneal dialysis patients with baseline plasma phosphorus >4.9 mg/dL | 500 mg | 8 weeks | 8 |
| Effect of niacin on the choroidal circulation of patients with age related macular degeneration 2004 · 500 mg niacin group · 12 AMD patients with bilateral drusen and visual acuity of 20/40 or better in the study eye; six received 500 mg niacin | 500 mg | 1 day | 6 |
| Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans 2009 · 500 mg daily nicotinamide · healthy volunteers | 500 mg | 7 days | — |
| Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients 2013 · Group 4: D/E with active niacin and fenofibrate placebo · Adults aged 21–65 with HIV/HAART-associated dyslipidemia | 500 mg | 24 weeks | — |
| Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients 2013 · Group 5: D/E with active fenofibrate and active niacin · Adults aged 21–65 with HIV/HAART-associated dyslipidemia | 500 mg | 24 weeks | — |
| Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients 2019 · experimental group · Non-melanoma skin cancer patients with positive HIF-1α and p53 expressions | 500 mg | 7 days | — |
| A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study) 2020 · LEVELIP DUO® · Adults aged 30–75 with moderately hypercholesterolemic, sub-optimal blood cholesterol levels, without other cardiovascular risk factors and not taking lipid-lowering drugs | 27 mg | 8 weeks | 43 |
| Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study 2019 · Nutraceutical combination · Adults aged 18–70 with low cardiovascular risk, in primary cardiovascular prevention, and LDL-C of 130–200 mg/dL | 16 mg | 12 weeks | 16 |
| Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease 2011 · Group B · Patients with ischaemic heart disease; age and sex not specified | 1 g | 24 weeks | 108 |
| Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial 2002 · 1000 mg/d ER niacin group · Adults with type 2 diabetes and dyslipidemia | 1 g | 16 weeks | 45 |
| Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients 1994 · Combination therapy (pravastatin and nicotinic acid) · Adults with combined hyperlipidaemia, with or without non-insulin-dependent diabetes; total cholesterol ≥6.5 mmol/L and triglycerides ≥2.5 mmol/L | 1 g | 12 weeks | 33 |
| Effects of extended-release niacin on lipoprotein subclass distribution 2003 · Niacin ER 1,000 mg/day · Patients with primary hypercholesterolemia; age and sex not reported | 1 g | 12 weeks | 21 |
| Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects 2001 · niacin · Patients with type IIb dyslipidemia, triglycerides 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl | 1 g | 16 weeks | 11 |
| Effect of niacin on the choroidal circulation of patients with age related macular degeneration 2004 · 250 mg niacin group · 12 AMD patients with bilateral drusen and visual acuity of 20/40 or better in the study eye; six received 250 mg niacin | 250 mg | 1 day | 6 |
| Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease 2000 · niacin · Patients with peripheral arterial disease; age and sex not stated | 1 g | 1 year | — |
| A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin 2003 · niacin ER/lovastatin 1,000/20 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified | 1 g | 28 weeks | — |
| Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins 2004 · niacin group · Adults with known coronary heart disease and HDL-C below 45 mg/dL; mean age 67 years | 1 g | 1 year | — |
| Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin 1992 · 1,000 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles | 1 g | 8 weeks | — |
| The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome 2007 · extended-release niacin · Adults with metabolic syndrome meeting Adult Treatment Panel III criteria | 1 g | 52 weeks | — |
| Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study) 2008 · NER/S 1,000/20 mg/day · High-risk patients with predominantly mixed dyslipidemia who were already at LDL cholesterol goals; ages and sex not specified | 1 g | 24 weeks | — |
| Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance 2009 · ER niacin treatment group · Adults with impaired glucose tolerance and HDL-C below 1.0 mmol/L, mean age 45.2 years; no additional comorbidities | 1 g | 26 weeks | — |
| Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome 2010 · ERN · Dyslipidemic adults with metabolic syndrome | 1 g | 24 weeks | — |
| Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia 2013 · ERN/LRPT 1g/20mg+SIMVA (10 or 20mg) · Patients with mixed hyperlipidemia and LDL-C 130–190 mg/dL, triglycerides 150–500 mg/dL, and above their NCEP ATP III risk-based LDL-C goal | 1 g | 12 weeks | — |
| Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia 2013 · ERN/LRPT 1g/20mg+SIMVA (10 or 20mg) · Patients with mixed hyperlipidemia and LDL-C 130–190 mg/dL, triglycerides 150–500 mg/dL, and above their NCEP ATP III risk-based LDL-C goal | 1 g | 12 weeks | — |
| Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia 2012 · ERN/LRPT · Patients with dyslipidemia; age and sex not specified | 1 g | 12 weeks | — |
| Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia 2012 · ERN/LRPT 1 g/20 mg + SIM 10 mg · Patients with dyslipidemia; age and sex not specified | 1 g | 12 weeks | — |
| Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia 2012 · ERN/LRPT 1 g/20 mg + SIM 20 mg · Patients with dyslipidemia; age and sex not specified | 1 g | 12 weeks | — |
| Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia 2012 · ERN/LRPT 1 g/20 mg + SIM 40 mg · Patients with dyslipidemia; age and sex not specified | 1 g | 12 weeks | — |
| Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians 2013 · Extended-release niacin · Adults with isolated low HDL-C and predicted 10-year CHD risk of at least 20%, without overt CHD; men and women | 750 mg | 12 weeks | — |
| Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia 2014 · Add-on-statin extended-release nicotinic acid/laropiprant · Patients with mixed dyslipidemia whose lipid targets were not achieved on a standard statin dose | 1 g | 12 weeks | — |
| A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD(+) Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial 2022 · RiaGev · Healthy active men and women aged 36–65 years | 480 mg | 8 days | 18 |
| Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers 1998 · 50 mg/day nicotinic acid group · Healthy smokers; age and sex not specified | 50 mg | 14 weeks | — |
| Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers 1998 · 100 mg/day nicotinic acid group · Healthy smokers; age and sex not specified | 100 mg | 14 weeks | — |
| Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients 2013 · E/S+N · Adults aged 18–79 with hyperlipidemia, LDL-C 130–190 mg/dL and triglycerides ≤500 mg/dL | 2 g | 24 weeks | 294 |
| The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration 2010 · extended-release niacin · Patients with coronary heart disease or a CHD equivalent, low LDL cholesterol and low HDL cholesterol, receiving stable statin treatment | 2 g | 426 days | 154 |
| Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients 2013 · N · Adults aged 18–79 with hyperlipidemia, LDL-C 130–190 mg/dL and triglycerides ≤500 mg/dL | 2 g | 24 weeks | 124 |
| MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study 2013 · niacin · Adults over age 65 with previous cardiovascular events or documented atherosclerosis | 1.5 g | 548 days | 72 |
| Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial 2000 · niacin · Adults with diabetes and diagnosed peripheral arterial disease | 3 g | 60 weeks | 64 |
| Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I 2004 · Extended-release niacin · Hypercholesterolemic subjects classified by LDL pattern A or B | 1.5 g | 14 weeks | 60 |
| Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I 2004 · Immediate-release niacin · Hypercholesterolemic subjects classified by LDL pattern A or B | 3 g | 14 weeks | 59 |
| Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial 2002 · 1500 mg/d ER niacin group · Adults with type 2 diabetes and dyslipidemia | 1.5 g | 16 weeks | 52 |
| Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) 1997 · Nicotinamide group · Patients aged 5–35 years with recent-onset insulin-dependent diabetes mellitus | 25 mg/kg | 1 year | 42 |
| Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia 2013 · WMER · Adults with mild-to-moderate dyslipidemia | 1.5 g | 6 weeks | 40 |
| Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia 2013 · IHN · Adults with mild-to-moderate dyslipidemia | 1.5 g | 6 weeks | 40 |
| Effect of Egg-White Protein Alone or Combined With Niacin on Nutritional Status, and Phosphorus Control in Maintenance Hemodialysis Patients: A Randomized Controlled Trial 2024 · 600 g niacin daily · Patients on maintenance hemodialysis | 600 g | 8 weeks | 24 |
| Extended-release niacin acutely suppresses postprandial triglyceridemia 2012 · extended-release niacin · Healthy, niacin-naive adults lacking all elements of metabolic syndrome; age and sex range not stated | 2 g | 1 day | 22 |
| Effects of extended-release niacin on lipoprotein subclass distribution 2003 · Niacin ER 2,000 mg/day · Patients with primary hypercholesterolemia; age and sex not reported | 2 g | 12 weeks | 20 |
| Extended-release niacin raises adiponectin and leptin 2007 · extended-release niacin · men with metabolic syndrome | 1.5 g | 6 weeks | 20 |
| Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study 2014 · Niaspan · Nondiabetic men with dyslipidemia and metabolic syndrome | 2 g | 8 weeks | 20 |
| Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy 2020 · ER-niacin · Adults with HIV on antiretroviral therapy, CD4 ≤ 350 cells/µl despite an undetectable viral load for at least 3 months | 2 g | 24 weeks | 20 |
| Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia 2015 · ER niacin added after fenofibric acid · Dyslipidemic participants taking atorvastatin; age and sex not reported | 2 g | — | 19 |
| Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial 2012 · ERN · Adults aged 40–69 with metabolic syndrome | 2 g | 16 weeks | 15 |
| Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome 2024 · ERN · Adults aged 40–69 with metabolic syndrome | 2 g | 16 weeks | 14 |
| Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus 1990 · nicotinic acid · Patients with non-insulin-dependent diabetes mellitus and dyslipidemia | 4.5 g | 8 weeks | 13 |
| Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass 2013 · Nicotinic acid group · Obese men; mean BMI 32.7 | 2 g | 8 weeks | 12 |
| A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia 1992 · nicotinic acid group · Patients with type 2b hyperlipidaemia; age and sex not reported | 3 g | 12 weeks | 7 |
| Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV 2025 · ART intensification + nicotinamide group (arm C) · Men aged 28–52 with HIV receiving suppressive ART for at least 2 years, with CD4+ T-cell counts above 500 cells/mm³ | 2 g | 48 weeks | 5 |
| Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV 2025 · dolutegravir + nicotinamide + auranofin + DC therapy group (arm F) · Men aged 25–61 with HIV receiving suppressive ART for at least 2 years, with CD4+ T-cell counts above 500 cells/mm³ | 2 g | 48 weeks | 5 |
| Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density 1999 · niacin and colestipol therapy · People with documented coronary disease, apolipoprotein B levels ≥125 mg/dL, and a family history of coronary artery disease; age and sex not reported | 4 g | — | — |
| Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study 2000 · NA · Patients with clinically well-defined atherosclerosis and isolated hypoalphalipoproteinemia | 2.25 g | — | — |
| Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia 2001 · immediate release niacin · Patients with atherogenic dyslipidemia, with total cholesterol >200 mg/dl, triglycerides 200–800 mg/dl, and apolipoprotein B >110 mg/dl; age and sex not reported. | 3 g | 12 weeks | — |
| A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin 2003 · niacin ER/lovastatin 2,000/40 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified | 2 g | 28 weeks | — |
| A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin 2003 · niacin ER 2,000 mg · Patients with type IIA or IIB hyperlipidemia; age and sex not specified | 2 g | 28 weeks | — |
| Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) 2004 · simvastatin plus niacin · Patients with coronary artery disease and low HDL cholesterol, with or without diabetes | 2.4 g | 3 years | — |
| Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin 1992 · 1,250 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles | 1.25 g | 8 weeks | — |
| Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin 1992 · 1,500 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles | 1.5 g | 8 weeks | — |
| Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin 1992 · 2,000 mg/day niacin group · Men and women aged 20–70 with hypercholesterolemia and baseline LDL cholesterol between the 75th and 95th percentiles | 2 g | 8 weeks | — |
| Preferential increase in high-molecular weight adiponectin after niacin 2008 · niacin · Men with metabolic syndrome | 1.5 g | 6 weeks | — |
| Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study 2008 · 8-week niacin titration scheme · Patients with mixed dyslipidemia; age and sex not reported | 2 g | 52 weeks | — |
| Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study 2008 · 12-week niacin titration scheme · Patients with mixed dyslipidemia; age and sex not reported | 2 g | 52 weeks | — |
| Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study) 2008 · NER/S 2,000/20 mg/day · High-risk patients with predominantly mixed dyslipidemia who were already at LDL cholesterol goals; ages and sex not specified | 2 g | 24 weeks | — |
| Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans 2009 · 1500 mg daily nicotinamide · healthy volunteers | 1.5 g | 7 days | — |
| Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia 2009 · nicotinic acid plus placebo · Patients with combined hyperlipidemia; age and sex not reported | 1.5 g | 12 weeks | — |
| Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia 2009 · nicotinic acid plus gemfibrozil · Patients with combined hyperlipidemia; age and sex not reported | 1.5 g | 12 weeks | — |
| A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability 1991 · nicotinic acid · Non-diabetic patients with type II B or IV hypertriglyceridaemia; ages and sex not stated | 3 g | 6 weeks | — |
| Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study 2009 · nicotinic acid group · Patients with low HDL-C and either type 2 diabetes with coronary heart disease or carotid/peripheral atherosclerosis; age and sex not reported | 2 g | 1 year | — |
| Extended-release niacin or ezetimibe and carotid intima-media thickness 2009 · extended-release niacin group · Patients with coronary heart disease or a coronary heart disease risk equivalent, receiving long-term statin therapy, with LDL cholesterol under 100 mg/dL and low HDL cholesterol | 2 g | 426 days | — |
| Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy 2010 · ER niacin · Patients with type 2 diabetes and low HDL meeting metabolic syndrome criteria | 1.5 g | 90 days | — |
| Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy 2010 · ERN (niacin) group · Adults aged 18 years or older with HIV infection, low HDL-c, and stable antiretroviral therapy | 1.5 g | 12 weeks | — |
| Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease 2010 · Niaspan (extended-release nicotinic acid) · Obese subjects with nonalcoholic fatty liver disease; age and sex not specified | 2 g | 16 weeks | — |
| Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg 2010 · niacin extended release group · Patients with triglyceride levels of 150–499 mg/dL, HDL-C below 45 mg/dL and LDL-C below 130 mg/dL; age and sex not stated | 1.5 g | 16 weeks | — |
| Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome 2010 · ERN/LRPT · Dyslipidemic adults with metabolic syndrome | 1 g | 24 weeks | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · FATS immediate-release niacin plus colestipol · Men with established coronary atherosclerosis, elevated apolipoprotein B and family history of coronary heart disease; baseline fasting glucose <100 mg/dl | 4 g | 3 years | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · HATS slow-release niacin plus simvastatin · Adults with coronary artery disease, angiographic coronary atherosclerosis and low HDL cholesterol; baseline fasting glucose <100 mg/dl | 2 g | 3 years | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · HATS slow-release niacin plus simvastatin and antioxidants · Adults with coronary artery disease, angiographic coronary atherosclerosis and low HDL cholesterol; baseline fasting glucose <100 mg/dl | 2 g | 3 years | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · AFREGS immediate-release niacin · Military retirees with angiographically documented coronary atherosclerosis and HDL cholesterol <40 mg/dl; baseline fasting glucose <100 mg/dl | 3 g | 3 years | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · CPC atorvastatin plus extended-release niacin · People with coronary or carotid artery disease, apolipoprotein B >120 mg/dl and less than one year of lipid therapy; baseline fasting glucose <100 mg/dl | 2 g | 3 years | — |
| Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study 2013 · CPC atorvastatin plus extended-release niacin and colesevelam · People with coronary or carotid artery disease, apolipoprotein B >120 mg/dl and less than one year of lipid therapy; baseline fasting glucose <100 mg/dl | 2 g | 3 years | — |
| Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia 2015 · simvastatin 20 mg/extended-release niacin combination · Patients with carotid atherosclerosis; age and sex not reported | 2 g | — | — |
| A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography 2015 · niacin · Patients with coronary disease receiving statin therapy; age and sex not reported | 6 g | 12 weeks | — |
| Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol 2015 · ERN · Overweight patients with elevated triglyceride/HDL-C ratios; age and sex not specified | 2 g | 16 weeks | — |
| Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH 2016 · ERN (extended-release niacin) · Adults aged 45 years or older with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia, receiving simvastatin and ezetimibe | 1.5 g | 3 years | — |
| Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk 2016 · niacin monotherapy · Adults aged 18–79 years with LDL-C levels of 130–190 mg/dL and triglyceride levels below 500 mg/dL | 2 g | 24 weeks | — |
| Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk 2016 · triple combination therapy of E/S/N · Adults aged 18–79 years with LDL-C levels of 130–190 mg/dL and triglyceride levels below 500 mg/dL | 2 g | 24 weeks | — |
| Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study 2018 · niacin–laropiprant · Men and women aged 50–80 with a history of myocardial infarction, cerebrovascular disease, peripheral arterial disease, or diabetes with other evidence of symptomatic coronary disease | 2 g | 4 years | — |
| Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients 1994 · Nicotinic acid alone · Adults with combined hyperlipidaemia, with or without non-insulin-dependent diabetes; total cholesterol ≥6.5 mmol/L and triglycerides ≥2.5 mmol/L | 1.5 g | 12 weeks | — |
| Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial 1995 · nicotinic acid · renal transplant patients with persistent hyperlipidemia despite 6 weeks of dietary treatment | 3 g | 16 weeks | — |
| Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia 1994 · increasing doses of crystalline niacin · Men with isolated low HDL-C and normal fasting cholesterol and triglyceride concentrations | 3 g | 12 weeks | — |
| Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety 1994 · Fluvastatin-niacin treated patients · Patients with hypercholesterolemia refractory to diet and LDL-C levels at least 160 mg/dL; age and sex not stated | 3 g | 9 weeks | — |
| Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety 1994 · Niacin-placebo control arm · Patients with hypercholesterolemia refractory to diet and LDL-C levels at least 160 mg/dL; age and sex not stated | 3 g | 9 weeks | — |
| Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia 1996 · 1500 mg/d CNA (ENDURACIN) phase · Men and women aged 20 to 70 years with hypercholesterolemia | 1.5 g | 60 days | — |
| Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia 1996 · 2000 mg/d CNA phase · Men and women aged 20 to 70 years with hypercholesterolemia | 2 g | 60 days | — |
| Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas 1998 · group 1: insulin plus nicotinamide · Adults with type 2 diabetes, normal body weight (BMI <25 kg/m2), no signs of autoimmunity, and secondary failure of sulphonylureas; age and sex not stated | 1.5 g | 26 weeks | — |
| Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas 1998 · group 3: current sulphonylureas plus nicotinamide · Adults with type 2 diabetes, normal body weight (BMI <25 kg/m2), no signs of autoimmunity, and secondary failure of sulphonylureas; age and sex not stated | 1.5 g | 26 weeks | — |
| Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia 1998 · Niaspan · Adult men and women with primary hypercholesterolemia | 1.5 g | 16 weeks | — |
| Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia 1998 · Plain niacin, 1.5 g/day phase · Adult men and women with primary hypercholesterolemia | 1.5 g | 8 weeks | — |
| SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs 1999 · Combination of pentifylline and nicotinic acid · Elderly volunteers aged 52–70 years, without a stated condition | 200 mg | 60 days | — |
| Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial 2012 · Combination · Adults aged 40–69 with metabolic syndrome | 2 g | 16 weeks | 13 |
| Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome 2024 · Combination · Adults aged 40–69 with metabolic syndrome | 2 g | 16 weeks | 13 |
| Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy 2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified | 50 mg | 45 days | — |
| Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy 2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified | 50 mg | 90 days | — |
| Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin 2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen | 50 mg | 45 days | — |
| Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin 2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen | 50 mg | 90 days | — |
| Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy 2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy | 50 mg | — | — |
| Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy 2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported | 50 mg | 45 days | — |
| Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy 2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported | 50 mg | 90 days | — |
| Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults 2013 · Q-1000 · Healthy adults aged 40–83 years; women and men | 10 mg | 90 days | — |
| Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults 2013 · Q-500 · Healthy adults aged 40–83 years; women and men | 5 mg | 90 days | — |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 20 mg | 10 weeks | 24 |
| Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial 2010 · antioxidant micronutrient combination · Patients with a history of sporadic colorectal adenoma; age and sex not specified | 80 mg | 120 days | — |
| Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial 2024 · intervention group · Critically ill patients with COVID-19 | 40 mg | 2 weeks | 40 |